2013•British Journal of HaematologyOpen access

An IgG3 switch variant of rituximab mediates enhanced complement‐dependent cytotoxicity against tumour cells with low CD 20 expression levels

Thies Rösner, Stefanie Derer, Christian Kellner, Michael Dechant, Stefan Lohse, Gestur Vidarsson, Matthias Peipp, Thomas Valerius

Open full text 25 citations

Abstract

The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

About this research paper

What this paper is about

Why it matters

OpenAlex reports 25 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Ofatumumab, Complement-dependent cytotoxicity, CD20, Rituximab, Antibody, Antigen, Antibody-dependent cell-mediated cytotoxicity, Immunology